Clear View Surgical Limited 31/08/2025 iXBRL

Company registration number: 12980966

Clear View Surgical Limited

Unaudited filleted financial statements

31 August 2025

Clear View Surgical Limited

Contents

Directors and other information

Accountants report

Statement of financial position

Notes to the financial statements

Clear View Surgical Limited

Directors and other information


	Directors	Luke Anderson
		Mario John Saldanha


	Company number	12980966


	Registered office	Sana, Axis Court Mallard Way
		Riverside Business Park
		Swansea
		SA70AJ


	Business address	Sana, Axis Court Mallard Way
		Riverside Business Park
		Swansea
		SA70AJ


	Accountants	Morgan Hemp
		103-104 Walter Road
		Swansea
		SA2 5QF

Clear View Surgical Limited

Report to the board of directors on the preparation of the

unaudited statutory financial statements of Clear View Surgical Limited

Year ended 31 August 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Clear View Surgical Limited for the year ended 31 August 2025 which comprise the statement of financial position and related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants , we are subject to its ethical and other professional requirements which are detailed at http://www.accaglobal.com/en/member/ professional-standards/ rules-standards/acca-rulebook.html.

This report is made solely to the board of directors of Clear View Surgical Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Clear View Surgical Limited and state those matters that we have agreed to state to the board of directors of Clear View Surgical Limited as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/content/dam/ACCA_Global /Technical/fact/technical-factsheet-163.pdf. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Clear View Surgical Limited and its board of directors as a body for our work or for this report.

It is your duty to ensure that Clear View Surgical Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Clear View Surgical Limited. You consider that Clear View Surgical Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Clear View Surgical Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Morgan Hemp

103-104 Walter Road

Swansea

SA2 5QF

15 October 2025

Clear View Surgical Limited

Statement of financial position

31 August 2025

		2025		2024
	Note	£	£	£	£

Fixed assets
Tangible assets	5	851,778		900,845
		_______		_______
			851,778		900,845

Current assets
Stocks		34,226		29,547
Debtors	6	190,642		233,513
Cash at bank and in hand		477,691		225,406
		_______		_______
		702,559		488,466
Creditors: amounts falling due
within one year	7	( 651,608)		( 853,802)
		_______		_______
Net current assets/(liabilities)			50,951		( 365,336)
			_______		_______
Total assets less current liabilities			902,729		535,509

Creditors: amounts falling due
after more than one year	8		( 593,157)		( 480,922)
			_______		_______
Net assets			309,572		54,587
			_______		_______

Capital and reserves
Called up share capital			110		110
Profit and loss account			309,462		54,477
			_______		_______
Shareholders funds			309,572		54,587
			_______		_______

For the year ending 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.

These financial statements were approved by the board of directors and authorised for issue on 15 October 2025 , and are signed on behalf of the board by:

Luke Anderson Mario John Saldanha

Director Director

Company registration number: 12980966

Clear View Surgical Limited

Notes to the financial statements

Year ended 31 August 2025

1. General information

The company is a private company limited by shares, registered in Wales. The address of the registered office is Sana, Axis Court Mallard Way, Riverside Business Park, Swansea, SA70AJ.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

When the outcome of a transaction involving the rendering of services can be reliably estimated, revenue from the rendering of services is measured by reference to the stage of completion of the service transaction at the end of the reporting period.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Operating leases

Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.

Tangible assets

tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 17 (2024: 13 ).

5. Tangible assets

	Long leasehold property	Plant and machinery	Total
	£	£	£
Cost
At 1 September 2024	820,254	320,928	1,141,182
Additions	16,583	135,649	152,232
	_______	_______	_______
At 31 August 2025	836,837	456,577	1,293,414
	_______	_______	_______
Depreciation
At 1 September 2024	82,026	158,311	240,337
Charge for the year	100,741	100,558	201,299
	_______	_______	_______
At 31 August 2025	182,767	258,869	441,636
	_______	_______	_______
Carrying amount
At 31 August 2025	654,070	197,708	851,778
	_______	_______	_______
At 31 August 2024	738,228	162,617	900,845
	_______	_______	_______

6. Debtors

	2025	2024
	£	£
Trade debtors	122,364	80,784
Other debtors	68,278	152,729
	_______	_______
	190,642	233,513
	_______	_______

7. Creditors: amounts falling due within one year

	2025	2024
	£	£
Bank loans and overdrafts	210,535	374,912
Trade creditors	91,012	39,551
Social security and other taxes	8,260	8,114
Other creditors	341,801	431,225
	_______	_______
	651,608	853,802
	_______	_______

8. Creditors: amounts falling due after more than one year

	2025	2024
	£	£
Bank loans and overdrafts	593,157	480,922
	_______	_______

9. Operating leases

The company as lessee

The total future minimum lease payments under non-cancellable operating leases are as follows:


	£	£

Not later than 1 year	46,712	67,451
Later than 1 year and not later than 5 years	44,062	59,264
Later than 5 years	492,781	546,300
	_______	_______
	583,555	673,015
	_______	_______

10. Related party transactions

Included in creditors is a balance of £11,709 (2024: £11,709) owed to the directors. The loan is interest free and repayment on demand. Included in creditors is a balance of £10,829 (2024: £84,429) owed to Landerson Eye Limited and £213 (2024: £46,413) owed to Sanmar Services Limited, companies connected to the directors. Included in cost of sales is £114,640 (2024: £77,800) paid to Landerson Eye Ltd and £59,720 (2024: £0) paid to Sanmar Services Ltd, companies connected to the directors.